Integrating artificial intelligence in drug discovery and early drug development: a transformative approach

Area of Science:

• Computational biology
• Pharmacology
• Bioinformatics

Background:

• Traditional drug discovery is inefficient, costly, and time-consuming.
• High failure rates plague conventional drug development pipelines.
• Artificial intelligence offers solutions to these inherent challenges.

Purpose of the Study:

• To provide an overview of AI integration in drug discovery and development.
• To highlight AI's role in enhancing key stages from target identification to clinical trials.
• To discuss the potential and limitations of AI in pharmaceutical research.

Main Methods:

• Multiomics data analysis and network-based approaches for target identification.
• AI models (e.g., AlphaFold) for protein structure prediction and druggability assessment.
• Virtual screening and de novo drug design for optimized molecular structures.

Main Results:

• AI identifies novel oncogenic vulnerabilities and therapeutic targets.
• Accurate protein structure prediction aids structure-based drug design.
• AI optimizes patient recruitment and clinical trial design using predictive modeling.

Conclusions:

• AI integration transforms drug discovery and development, accelerating timelines.
• Addressing data bias, generalizability, and ethical concerns is crucial for AI implementation.
• Collaboration and high-quality data are essential for realizing AI's full potential in accelerating drug development.